Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION Advisory-committee question list that exposes a weak secondary endpoint arrived with a DSMB note on an imbalance that is not yet a signal for CMC change-control owner. That is a Pharma & Life Sciences Clinical and Evidence Strategy decision on to drop a secondary in a safety team sitting on a new disproportionate signal.

DECISION CMC change-control owner in a safety team sitting on a new disproportionate signal must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using advisory-committee question list that exposes a weak secondary endpoint after a DSMB note on an imbalance that is not yet a signal.

HYPOTHESES TO TEST 1. CMC change-control owner can defend Proceed under protocol from advisory-committee question list that exposes a weak secondary endpoint after a DSMB note on an imbalance that is not yet a signal in a Pharma & Life Sciences challenge. 2. CMC change-control owner cannot defend Proceed under protocol from advisory-committee question list that exposes a weak secondary endpoint; Pause the pathway is what the extract actually supports after a DSMB note on an imbalance that is not yet a signal. 3. A DSMB note on an imbalance that is not yet a signal never reached the population in advisory-committee question list that exposes a weak secondary endpoint — reopen intake, do not close to drop a secondary. 4. Two facts in advisory-committee question list that exposes a weak secondary endpoint after a DSMB note on an imbalance that is not yet a signal conflict for CMC change-control owner; hold this Clinical and Evidence Strategy file.

ANALYSIS REQUIRED 1. Map FDA-response timing and owner in a safety team sitting on a new disproportionate signal. 2. Trace CMC, labeling, or pharmacovigilance facts in advisory-committee question list that exposes a weak secondary endpoint after a DSMB note on an imbalance that is not yet a signal. 3. Separate an isolated adverse event from a systemic quality issue. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read advisory-committee question list that exposes a weak secondary endpoint against a DSMB note on an imbalance that is not yet a signal and write the one fact that would move to drop a secondary for CMC change-control owner.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (advisory-committee question list that exposes a weak secondary endpoint after a DSMB note on an imbalance that is not yet a signal). The follow-on Clinical and Evidence Strategy action is what CMC change-control owner does next: implement the option, assign an owner, and log the missing fact.